Form 4: Day One Biopharmaceuticals Executive Michael Vasconcelles Granted Significant Equity Awards

Michael Vasconcelles, Head of Research and Development at Day One Biopharmaceuticals, Inc., was granted 346,000 stock options and 226,000 Restricted Stock Units on June 16, 2025.

Summary

• Michael Vasconcelles, Head of Research and Development at Day One Biopharmaceuticals, Inc. (DAWN), acquired new equity awards.
• He was granted 346,000 stock options with an exercise price of $6.64 per share.
• These stock options begin vesting on June 16, 2026, with 1/4th of the total grant vesting, followed by 1/48th monthly thereafter, subject to continued service.
• The stock options have an expiration date of June 15, 2035.
• Additionally, he received 226,000 Restricted Stock Units (RSUs), where each RSU represents a contingent right to receive one share of common stock for no consideration.
• The RSUs will vest 25% of the total award on August 15, 2026, with the remaining RSUs vesting in quarterly installments thereafter on November 15, February 15, May 15, and August 15, subject to continued service.
• The total number of derivative securities beneficially owned by Mr. Vasconcelles following these transactions is 346,000 stock options and 226,000 RSUs.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity grant to a key executive, which is generally a positive sign for executive retention and alignment with shareholder interests, without any negative implications.

Positives

• The grant of 346,000 stock options and 226,000 Restricted Stock Units aligns the executive's interests with long-term shareholder value.
• Equity grants are a common form of executive compensation, indicating retention and motivation of key personnel like the Head of Research and Development.

Future Outlook

The vesting schedules for both stock options and Restricted Stock Units extend several years into the future, indicating a long-term incentive structure for the Head of Research and Development, contingent on continued service to the company.

Industry Context

The granting of equity awards to key executives like the Head of Research and Development is a standard practice in the biopharmaceutical industry, aiming to incentivize long-term commitment, innovation, and performance, especially given the long development cycles inherent in drug discovery.

Comparison to Industry Standards

• The structure of these equity grants, including a mix of stock options and Restricted Stock Units with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biopharmaceutical sector for similar roles.
• While specific comparable companies or projects are not detailed in this filing, such grants are common for executives at growth-stage biotech firms like Day One Biopharmaceuticals, Inc., to align their incentives with shareholder value creation over time.

Stakeholder Impact

• Shareholders: The grants align the interests of a key executive with shareholders, potentially leading to better long-term performance.
• Employees: May signal stability and a commitment to retaining key talent within the company.
• Management: Reinforces the compensation structure for senior leadership, incentivizing long-term performance and retention.

Next Steps

• Continued provision of service by Michael Vasconcelles to the Issuer for the equity awards to vest according to their respective schedules.
• Future SEC filings (Form 4) will report any subsequent changes in beneficial ownership by Michael Vasconcelles.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, SEC Form 4, Michael Vasconcelles, Stock Options, Restricted Stock Units, RSU, Equity Grant, Executive Compensation, Insider Transaction, Biopharmaceuticals, Research and Development